Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China

Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China

Background The 9-valent human papillomavirus (9vHPV) vaccine was introduced in China in 2018. This study was conducted to monitor the occurrence of new-onset autoimmune diseases (AIs) in Chinese women vaccinated with the 9vHPV vaccine and adverse pregnancy outcomes in infants born to mothers with in...

Full description

Bibliographic Details
Main Authors: Ruogu Meng, Rui Ma, Jianmei Wang, Peipei Liu, Zuoxiang Liu, Bingjie He, Zhike Liu, Yu Yang, Siyan Zhan
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Expert Review of Vaccines
Subjects:
9-valent human papillomavirus vaccine
safety
product surveillance
post-marketing
autoimmune diseases
pregnancy
Online Access:http://dx.doi.org/10.1080/14760584.2023.2239911

Similar Items

Similar Items